Avodart (Dutasteride) Cost in North Dakota: 2026 Pricing, Insurance, and Savings Guide

How Much Does Avodart (Dutasteride) Cost in North Dakota in 2026?
At a glance
- Brand Avodart list price / $290 per month (GSK)
- Generic dutasteride cash price / approximately $25 per month in ND
- Compounded dutasteride (503A) / approximately $40 per month
- North Dakota Medicaid / not covered
- Medicare Part D / generic usually covered, Tier 2
- Dose and form / 0.5 mg oral capsule, once daily
- Telehealth prescribing in ND / yes, permitted
- FDA-approved indication / benign prostatic hyperplasia (BPH)
- Off-label use / androgenetic alopecia (male pattern hair loss)
- Compounding legality in ND / yes, via licensed 503A pharmacies
Brand vs. Generic vs. Compounded: Price Breakdown
The gap between brand Avodart and its generic equivalent is among the widest in the 5-alpha reductase inhibitor class. GSK's brand product carries a wholesale acquisition cost (WAC) near $290 per month for a 30-count supply of 0.5 mg soft-gelatin capsules. Generic dutasteride, available since the FDA approved the first generic formulations in late 2015, now averages about $25 per month across North Dakota pharmacies.
Why Generics Are So Much Cheaper
Patent expiration allowed multiple manufacturers to enter the market, and dutasteride's relatively simple capsule formulation kept manufacturing costs low. A 2020 analysis in the Journal of Managed Care & Specialty Pharmacy found that generic 5-alpha reductase inhibitor prices fell more than 85% within five years of initial generic approval.
Compounded Dutasteride Pricing
Compounded dutasteride through a North Dakota-licensed 503A pharmacy costs approximately $40 per month. That premium over generic reflects the smaller batch sizes and custom formulation work involved. Compounding may be relevant for patients who need a non-standard dose or combined formulation (for example, dutasteride with minoxidil in a topical preparation). The FDA's guidance on 503A compounding requires a valid patient-specific prescription and a licensed pharmacist.
North Dakota Medicaid Coverage
North Dakota Medicaid does not cover Avodart or generic dutasteride on its preferred drug list as of 2026. The state's Medicaid formulary, administered through Magellan Rx Management, classifies dutasteride as non-preferred with no prior authorization pathway for BPH. Patients on North Dakota Medicaid who need a 5-alpha reductase inhibitor are typically directed to finasteride, which the AUA guidelines list as an equivalent first-line option for symptomatic BPH.
What Medicaid Patients Can Do
For patients whose clinician specifically recommends dutasteride over finasteride, the options include paying the $25 per month generic cash price out of pocket, applying for GSK's patient assistance program, or requesting a therapeutic exception through the state's Medicaid office. The AUA's 2010 BPH guideline update notes that dutasteride and finasteride show comparable efficacy for prostate volume reduction, though dutasteride inhibits both type 1 and type 2 5-alpha reductase isoenzymes while finasteride targets only type 2 [1].
Commercial Insurance and Medicare Part D
Most commercial insurers operating in North Dakota, including Blue Cross Blue Shield of North Dakota, Sanford Health Plan, and Medica, cover generic dutasteride on Tier 2 with copays between $5 and $30 per month. Brand Avodart is typically Tier 3 or non-preferred, requiring prior authorization and producing copays of $50 to $100 or more.
Medicare Part D Formulary Placement
Medicare Part D plans generally include generic dutasteride. Under the Inflation Reduction Act's $2,000 annual out-of-pocket cap that took full effect in 2025, even patients who fill multiple prescriptions benefit from lower cumulative spending. A patient taking only generic dutasteride at $25 per month would spend $300 annually at cash price, well below the cap even without plan coverage.
Step Therapy Requirements
Some plans require documentation that finasteride was tried first or is contraindicated before approving dutasteride. A meta-analysis published in The Lancet (N = 4,481 across three head-to-head trials) found dutasteride achieved statistically greater prostate volume reduction than finasteride at 12 months (26.1% vs. 21.5%), which can support step-therapy override requests.
Discount Programs and Savings Cards
Several savings paths exist for North Dakota patients paying out of pocket or facing high copays.
GSK Savings Card
GSK historically offered a manufacturer savings card for brand Avodart that reduced copays to as low as $30 per month for commercially insured patients. Card eligibility excludes government-insured patients (Medicare, Medicaid, Tricare). Check GSK's current enrollment portal, as program terms change annually.
Pharmacy Discount Platforms
Platforms like GoodRx, RxSaver, and SingleCare negotiate discounted rates with pharmacies. In Bismarck and Fargo, these platforms show generic dutasteride prices between $12 and $30 for a 30-day supply as of May 2026. Prices vary by pharmacy, so comparing across locations is worthwhile. The FDA notes that generic drugs must meet the same bioequivalence standards as brand products, so switching to a cheaper generic manufacturer carries no therapeutic penalty.
Patient Assistance Programs
Uninsured patients with household income below 300% of the federal poverty level may qualify for manufacturer-sponsored free drug programs. NeedyMeds and RxAssist maintain searchable databases of active programs. For dutasteride specifically, several generic manufacturers run limited assistance programs through wholesale distributors.
Compounded Dutasteride Legality in North Dakota
Compounded dutasteride is legal in North Dakota when dispensed by a pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. The pharmacy must compound from bulk drug substances that appear on the FDA's list, hold a valid North Dakota Board of Pharmacy license, and fill prescriptions for individually identified patients.
503A vs. 503B Outsourcing Facilities
A 503A pharmacy compounds patient-specific prescriptions. A 503B outsourcing facility can produce larger batches without patient-specific prescriptions but faces FDA inspection requirements similar to conventional manufacturers. Both routes are available to North Dakota prescribers. Topical compounded dutasteride (often 0.1% to 0.5% in a penetrating base) has gained interest for androgenetic alopecia, though it remains off-label.
Clinical Evidence for Compounded Topical Dutasteride
A randomized controlled trial by Eun et al. (J Am Acad Dermatol, 2010) demonstrated that mesotherapy-delivered dutasteride improved hair counts in men with androgenetic alopecia compared to placebo at 18 weeks [2]. While this study used an injectable micro-delivery method rather than a topical cream, it established proof of concept for localized dutasteride delivery. A more recent 2022 prospective study published in Dermatologic Therapy found that topical dutasteride 0.1% applied daily produced measurable hair density improvements at 24 weeks with lower serum DHT suppression than oral dosing.
Telehealth Prescribing in North Dakota
North Dakota permits telehealth prescribing of dutasteride. The state's telemedicine parity law, updated in 2021, allows prescribers to establish a patient-physician relationship via synchronous audio-video visit. A 2021 JAMA Dermatology study found that teledermatology visits for hair loss produced concordant treatment plans with in-person visits in 87% of cases.
How to Get a Prescription Via Telehealth
Schedule a video consultation with a urologist or dermatologist licensed in North Dakota. The clinician will review symptoms, medical history (including liver function, since dutasteride is hepatically metabolized), and any prior treatment with finasteride. If appropriate, they can e-prescribe dutasteride to any North Dakota pharmacy, including mail-order and compounding pharmacies. No in-person visit is required for an initial prescription under current North Dakota Board of Medicine rules.
Clinical Context: What Dutasteride Treats
Dutasteride 0.5 mg daily is FDA-approved for symptomatic benign prostatic hyperplasia in men with an enlarged prostate. The drug inhibits both type 1 and type 2 isoforms of 5-alpha reductase, reducing serum dihydrotestosterone (DHT) by approximately 90% [3]. By comparison, finasteride inhibits only the type 2 isoform and reduces DHT by roughly 70%.
BPH Efficacy Data
The CombAT trial (N = 4,844), a four-year randomized study published in European Urology, showed that dutasteride plus tamsulosin reduced the relative risk of acute urinary retention or BPH-related surgery by 65.8% compared with tamsulosin alone. The combination also produced a 27.3% reduction in total prostate volume at 48 months [4].
Hair Loss Use (Off-Label)
Although not FDA-approved for androgenetic alopecia, dutasteride is widely prescribed off-label for male pattern hair loss. A phase III trial (Olsen et al., J Am Acad Dermatol, 2006) comparing dutasteride 0.5 mg daily to finasteride 1 mg daily found that dutasteride produced significantly greater increases in target area hair count at 24 weeks (12.2% vs. 4.7% increase from baseline). A Korean randomized trial (N = 153) published in the Journal of the American Academy of Dermatology in 2018 confirmed superiority of dutasteride 0.5 mg over finasteride 1 mg at 24 weeks for vertex hair count improvement.
Side Effects and Cost-Benefit Considerations
The most common adverse effects of dutasteride include decreased libido (reported in 3.3% of patients vs. 1.5% on placebo), erectile dysfunction (5.1% vs. 2.0%), and ejaculation disorders (1.8% vs. 0.5%), based on the pooled phase III data in the FDA label [5]. These rates are modestly higher than those reported for finasteride.
Long-Term Safety Signals
The REDUCE trial (N = 8,231), a four-year chemoprevention study, found that dutasteride reduced overall prostate cancer incidence by 22.8% (relative risk reduction) but was associated with a small absolute increase in high-grade (Gleason 8 to 10) cancers detected in years 3 and 4. The FDA subsequently added a label warning about this signal in 2011, though the clinical significance remains debated.
When the Price Premium Over Finasteride Makes Sense
At $25 per month for generic dutasteride vs. Roughly $10 per month for generic finasteride, dutasteride costs about $180 more per year. That premium may be justified for patients with large prostates (greater than 40 mL), those who showed inadequate DHT suppression on finasteride, or men seeking maximal hair count improvement based on the head-to-head trial data.
Practical Steps to Lower Your Dutasteride Cost in North Dakota
Start by confirming whether your insurance formulary covers generic dutasteride. If it does, your copay will likely fall between $5 and $30. If you are uninsured or your plan excludes dutasteride, compare cash prices at local pharmacies using a discount platform. Fargo, Bismarck, Grand Forks, and Minot pharmacies all stock generic dutasteride. Mail-order pharmacies (including those affiliated with Express Scripts and OptumRx) sometimes offer 90-day supplies for less than three times the 30-day price. Ask your prescriber about 90-day fills, which can reduce per-unit cost and pharmacy dispensing fees by up to 20% according to a JAMA Internal Medicine analysis of mail-order prescription savings.
Frequently asked questions
›How much does Avodart cost in North Dakota?
›Does North Dakota Medicaid cover Avodart?
›Is compounded dutasteride legal in North Dakota?
›Can I get Avodart via telehealth in North Dakota?
›Which insurance plans cover Avodart in North Dakota?
›What's the cheapest way to get Avodart in North Dakota?
›Are there North Dakota Avodart discount programs?
›How does the GSK savings card work in North Dakota?
›Is dutasteride better than finasteride for hair loss?
›Does dutasteride require blood work before starting?
›Can women take dutasteride?
›How long does dutasteride take to work for BPH?
References
- Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60(3):434-441.
- Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg combined with intradermal dutasteride injection in male androgenetic alopecia. J Am Acad Dermatol. 2010;63(6):1015-1023.
- Clark RV, Hermann DJ, Cunningham GR, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5-alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89(5):2179-2184.
- Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123-131.
- GlaxoSmithKline. Avodart (dutasteride) prescribing information. FDA Access Data. 2020.
- Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192-1202.
- Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5-alpha-reductase inhibition in the treatment of male pattern hair loss. J Am Acad Dermatol. 2006;55(6):1014-1023.
- Tsunemi Y, Irisawa R, Yoshiie H, et al. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. J Dermatol. 2016;43(9):1051-1058.
- FDA Drug Safety Communication. 5-alpha reductase inhibitors may increase the risk of a more serious form of prostate cancer. FDA.gov. 2011.
- Choudhry NK, Shrank WH, Fischer MA, et al. Assessment of mail-order pharmacy savings. JAMA Intern Med. 2019;179(1):100-101.
- Barbieri JS, Shin DB, Engelman D, et al. Concordance of management decisions from store-and-forward teledermatology compared with in-person visits. JAMA Dermatol. 2021;157(5):595-597.
- FDA. Generic drug facts. FDA.gov.
- FDA. Compounding and the FDA: questions and answers. FDA.gov.
- Nickel JC, Gilling P, Tammela TL, et al. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the EPICS trial. BJU Int. 2011;108(3):388-394.
- FDA. Section 503B of the Federal Food, Drug, and Cosmetic Act. FDA.gov.